This proposed study is to overcome one of the current critical challenges of adaptive immunotherapy of cancer. We propose a novel approach to sustain the function of T cell co-stimulatory machinery and thus to empower the effectiveness and persistence of tumor-specific T cell activation. We anticipate that the outcome of our study would have significant impact on improving current practice for cancer immunotherapy, such as therapies of immune checkpoint blockade and adoptive T cell transfer.
|Effective start/end date||9/1/17 → 8/31/21|
- National Cancer Institute (5R01CA208246-05)